PIK3CA and prostate carcinoma: Our in silico results have indicated that CD133 can be associated with the signaling factors of PI3K/Akt and MAPK pathways; this hypothesis was strengthened by the evidence of CD133’s impact on the PI3K/Akt pathway in prostate cancer [18].